Plasma α-synuclein predicts cognitive decline in Parkinson’s disease
暂无分享,去创建一个
Ming-Jang Chiu | Chin-Hsien Lin | Jen-Jie Chieh | Hsin-Hsien Chen | M. Chiu | Shieh-Yueh Yang | H. Horng | J. Chieh | Herng-Er Horng | Shieh-Yueh Yang | Che-Chuan Yang | Bing-Hsien Liu | Chin-Hsien Lin | Che-Chuan Yang | Bing-Hsien Liu | Hsin‐Hsien Chen
[1] M. Chiu,et al. Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles , 2016, Journal of Nanobiotechnology.
[2] H. Berendse,et al. Reduced α‐synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity , 2014, European journal of neurology.
[3] Paolo Barone,et al. The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.
[4] Tessandra H Stewart,et al. Alpha‐Synuclein as a Biomarker for Parkinson's Disease , 2016, Brain pathology.
[5] M. Farrer,et al. Parkin mutations and early-onset parkinsonism in a Taiwanese cohort. , 2005, Archives of neurology.
[6] Ekaterina Nosova,et al. α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease , 2016, Annals of neurology.
[7] M. Sugishita,et al. [Clinical Dementia Rating (CDR)]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.
[8] P. Lee,et al. The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy , 2006, Journal of Neural Transmission.
[9] V. Calabrese,et al. PROJECTED NUMBER OF PEOPLE WITH PARKINSON DISEASE IN THE MOST POPULOUS NATIONS, 2005 THROUGH 2030 , 2007, Neurology.
[10] Ya-Fang Chen,et al. Plasma tau as a window to the brain—negative associations with brain volume and memory function in mild cognitive impairment and early alzheimer's disease , 2014, Human brain mapping.
[11] J. Trojanowski,et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease , 2010, Neurology.
[12] J. Trojanowski,et al. Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies , 2013, Nature Reviews Neuroscience.
[13] N. Mattsson. CSF biomarkers in neurodegenerative diseases , 2011, Clinical chemistry and laboratory medicine.
[14] K. Blennow,et al. Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.
[15] R. Barker,et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines , 2012, Movement disorders : official journal of the Movement Disorder Society.
[16] M. Cookson,et al. α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[17] K. Cain,et al. Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. , 2014, The American journal of pathology.
[18] A. Fallgatter,et al. Alpha-Synuclein Levels in Blood Plasma Decline with Healthy Aging , 2015, PloS one.
[19] Sonja W. Scholz,et al. Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.
[20] A. Siderowf,et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease , 2009, Neurology.
[21] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[22] Henrik Zetterberg,et al. CSF biomarkers and clinical progression of Parkinson disease , 2015, Neurology.
[23] L. Silveira-Moriyama,et al. Non-motor signs in Parkinson's disease: a review. , 2015, Arquivos de neuro-psiquiatria.
[24] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[25] E. Tolosa,et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[26] J. Jankovic,et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.
[27] T. J. Cook,et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease , 2014, Acta Neuropathologica.
[28] E. Tan,et al. Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore , 2008, Neurology.
[29] M. Rodriguez-Oroz,et al. Biomarkers for dementia and mild cognitive impairment in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.
[30] N. Bargalló,et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. , 2013, Parkinsonism & related disorders.
[31] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[32] W Poewe,et al. Diagnosis and management of Parkinson's disease dementia , 2008, International journal of clinical practice.
[33] Arthur W Toga,et al. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. , 2013, JAMA neurology.
[34] Brit Mollenhauer,et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.
[35] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[36] K. Cain,et al. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease. , 2015, Parkinsonism & related disorders.
[37] C. Tanner,et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 , 2007, Neurology.
[38] Johan Marinus,et al. Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUT , 2004, Movement disorders : official journal of the Movement Disorder Society.
[39] Ming-Jang Chiu,et al. Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro. , 2011, ACS chemical neuroscience.
[40] C. Summerfield,et al. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. , 2002, Archives of neurology.
[41] T. Tokuda,et al. Decrease in Plasma Levels of α-Synuclein Is Evident in Patients with Parkinson’s Disease after Elimination of Heterophilic Antibody Interference , 2015, PloS one.
[42] H. Braak,et al. Review: Sporadic Parkinson's disease: development and distribution of α‐synuclein pathology , 2016, Neuropathology and applied neurobiology.
[43] R. Wu,et al. Biomarkers of cognitive decline in Parkinson's disease. , 2015, Parkinsonism & related disorders.